Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,599,549
  • Shares Outstanding, K 111,490
  • Annual Sales, $ 74,910 K
  • Annual Income, $ -761,500 K
  • 60-Month Beta 2.47
  • Price/Sales 182.13
  • Price/Cash Flow N/A
  • Price/Book 8.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -2.21
  • Number of Estimates 7
  • High Estimate -1.92
  • Low Estimate -2.39
  • Prior Year -2.09
  • Growth Rate Est. (year over year) -5.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
88.93 +37.15%
on 11/14/19
123.90 -1.56%
on 12/04/19
+29.92 (+32.50%)
since 11/05/19
3-Month
73.32 +66.35%
on 10/02/19
123.90 -1.56%
on 12/04/19
+38.83 (+46.70%)
since 09/05/19
52-Week
60.27 +102.37%
on 12/24/18
123.90 -1.56%
on 12/04/19
+43.62 (+55.67%)
since 12/04/18

Most Recent Stories

More News
Trade of the 2020's: Sell Gold, Buy Biotech

In 5 years, you be selling your gold and buying more companies leading the century of biology.

IBB : 118.55 (-1.54%)
ALNY : 123.41 (+1.17%)
NVDA : 208.92 (-0.24%)
CME : 205.96 (+0.58%)
CRSP : 70.79 (-1.82%)
SmarTrend Watching for Potential Pullback in Shares of Alnylam Pharmace After 2.97% Gain

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $119.90 to a high of $122.40. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high...

ALNY : 123.41 (+1.17%)
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG

The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG

GLD : 139.15 (+0.17%)
ALNY : 123.41 (+1.17%)
GBT : 75.01 (+1.12%)
CRSP : 70.79 (-1.82%)
ARKG : 33.94 (-1.48%)
Alnylam Gets Second Product Approval Amid Stiff Competition

Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.

SNY : 46.23 (-0.82%)
ALNY : 123.41 (+1.17%)
MDCO : 84.05 (-0.02%)
REGN : 367.45 (-0.68%)
Why Gold is Headed to Zero -- And What You Should Buy Instead

Why Gold is Headed to Zero -- And What You Should Buy Instead

TSLA : 328.80 (-1.27%)
IBB : 118.55 (-1.54%)
GLD : 139.15 (+0.17%)
GBT : 75.01 (+1.12%)
CRSP : 70.79 (-1.82%)
ARKG : 33.94 (-1.48%)
ALNY : 123.41 (+1.17%)
Alnylam Pharmaceuticals, Inc. (ALNY) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Alnylam Pharmaceuticals, Inc. (ALNY).

ALNY : 123.41 (+1.17%)
Alnylam to Webcast Presentations at Upcoming December Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

ALNY : 123.41 (+1.17%)
Alnylam Pharmace Has Returned 31.2% Since SmarTrend Recommendation (ALNY)

SmarTrend identified an Uptrend for Alnylam Pharmace (NASDAQ:ALNY) on October 21st, 2019 at $85.25. In approximately 1 month, Alnylam Pharmace has returned 31.24% as of today's recent price of $111.88....

ALNY : 123.41 (+1.17%)
Alnylam Pharmace Set to Possibly Pullback After Yesterday's Rally of 4.65%

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $110.74 to a high of $116.50. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high...

ALNY : 123.41 (+1.17%)
The Medicines Company to be Acquired by Novartis for $9.7B

The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.

NVS : 91.74 (+0.20%)
MDCO : 84.05 (-0.02%)
ALNY : 123.41 (+1.17%)
AMGN : 231.89 (-0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade ALNY with:

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

2nd Resistance Point 126.03
1st Resistance Point 124.01
Last Price 123.41
1st Support Level 119.85
2nd Support Level 117.73

See More

52-Week High 123.90
Last Price 123.41
Fibonacci 61.8% 99.60
Fibonacci 50% 92.09
Fibonacci 38.2% 84.58
52-Week Low 60.27

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar